祭祀に登録されているコンテンツの著作権は、執筆者、出版社（学協会）などが有します。

祭祀に登録されているコンテンツの利用については、著作権法に規定されている私的使用や引用などの範囲内で行ってください。

著作権法に規定されている私的使用や引用などの範囲を超える利用を行う場合には、著作権者の許諾を得てください。ただし、著作権者が著作権等管理事業者（学術著作権協会、日本著作出版権管理システムなど）に権利委託されているコンテンツの利用手続については、各著作権等管理事業者に確認してください。

<table>
<thead>
<tr>
<th>項目</th>
<th>内容</th>
</tr>
</thead>
<tbody>
<tr>
<td>書籍名</td>
<td>金沢大学学術情報リポジトリ</td>
</tr>
<tr>
<td>タイトル</td>
<td>Treatment and impact of dyslipidemia in diabetic nephropathy</td>
</tr>
<tr>
<td>著者</td>
<td>Toyama, Tadashi; Shimizu, Miho; Furuichi, Kengo; Kaneko, Shuichi; Wada, Takashi</td>
</tr>
<tr>
<td>引用</td>
<td>Clinical and Experimental Nephrology, 18(2): 201-205</td>
</tr>
<tr>
<td>発行年</td>
<td>2014</td>
</tr>
<tr>
<td>タイプ</td>
<td>Journal Article</td>
</tr>
<tr>
<td>テキストバージョン</td>
<td>author</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/2297/39060">http://hdl.handle.net/2297/39060</a></td>
</tr>
</tbody>
</table>
This article is special featured issue of "WCN 2013 Satellite Symposium, Kidney and Lipids".

Title: Treatment and Impact of Dyslipidemia in Diabetic Nephropathy

Tadashi Toyama\textsuperscript{1)}, Miho Shimizu\textsuperscript{1)}, Kengo Furuichi\textsuperscript{1)}, Shuichi Kaneko\textsuperscript{2)}, Takashi Wada\textsuperscript{1),3)}

1) Division of Nephrology, Kanazawa University Hospital, Kanazawa, Japan.
2) Department of Disease Control and Homeostasis, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
3) Department of Laboratory Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.

Keywords: diabetic nephropathy, dyslipidemia, cardiovascular disease, end stage renal disease
Recent epidemiological researches reveal that dyslipidemia is a risk factor for development and progression of diabetic nephropathy. Results from interventional studies provided possibilities that anti-hyperlipidemic agents have better effect on diabetic nephropathy through improvement of albuminuria and loss of renal functions. In addition, dyslipidemia may be consequent on albuminuria and renal dysfunction, thereby perpetuating kidney damage. In these days, proportion of diabetic patients receiving the treatment of statins is increasing for its better effect on cardiovascular
mortality. However, treatment for patients should be determined based on consideration of the risk and benefit of the treatments. More insights into pathogenesis of diabetic nephropathy and effects of life-style changes are required.

Introduction

In the past epidemiological research in diabetes has found that albuminuria and renal dysfunction are dominant risk factors for the progression of diabetic nephropathy. Some interventional studies have revealed that strict glycemic control reduces the risk of development and progression of albuminuria [1][2].

It is a crucial fact that diabetic patients are at high risk of cardiovascular events. To prevent these events, dyslipidemia should be carefully controlled because it is one of the well-known risk factors. Statins and fibrates are representative drugs for dyslipidemia. Besides reducing plasma cholesterol levels they are thought to have many pleiotropic effects.
including improvement of endothelial function and inflammation[3][4]. However, treatment of patients with dyslipidemia is very complicated because it is not a simple metabolic disorder but closely related to the patients’ lifestyle. For this reason, lowering the level of cholesterol will not always result in a reduction of the risks.

In this manuscript, we will focus on the treatment and impact of dyslipidemia on the progression of diabetic nephropathy.

Dyslipidemia as a complication of diabetic nephropathy

The cross-sectional study implied that patients with diabetic nephropathy had significant increases in triglycerides and total cholesterol levels, reduced levels of ApoA-I and ApoA-II, and increased levels of apoC-II and apoC-III[5]. Other cross-sectional studies for patients of DCCT/EDIC revealed that high levels of triglycerides, LDL cholesterol, total cholesterol, and ApoB are associated with albuminuria[6]. ApoB is a apolipoprotein which is thought to be related to cardiovascular events in some studies[7][8].
In this way, the studies revealed the relationships between profiles of lipids and diabetic nephropathy.

Cardiovascular events are also very important complications in diabetic patients[9]. A meta-analysis reported the relation of dyslipidemia and cardiovascular risk [10], however, risks for diabetic patients are not well known.

**Dyslipidemia and loss of renal function**

The “Lipid nephrotoxicity” hypothesis was advocated by Moorhead in 1982 as a description of the effect of dyslipidemia on renal dysfunction[11]. Under this hypothesis, mesangial proliferation caused by accumulations of lipoprotein into mesangial cells induces glomerulosclerosis. This theory has been updated recently including the concept of inflammation stress modifying lipid homeostasis and tissue lipid accumulation[12] According to diabetes and lipids, Hartroft discovered in 1954 that intraluminal fat was found in both preglomerular and postglomerular vessels of diabetics patients
with Kimmelstiel-Wilson lesions[13]. In addition to this study, lots of basic research have discovered the mechanisms between dyslipidemia and diabetic nephropathy [14][15][16].

Some epidemiologic studies of general cohorts have elucidated the relationships between dyslipidemia and loss of renal function. The Framingham offspring study which consists of 1,916 general population subjects with a follow-up of 9.5 years, revealed that low HDL cholesterol levels is one of the risk factors for incident albuminuria[17]. An analysis of 1,440 general Japanese cohorts participated in the Hisayama study provided the fact that metabolic syndrome defined as the presence of components including high triglyceride levels and low HDL cholesterol levels are associated with a risk of developing CKD[18]. A study among 4,483 healthy males revealed that dyslipidemia including high total cholesterol levels, high non-HDL cholesterol levels, and low HDL cholesterol levels are associated with a risk of renal dysfunction [19].

According to these facts, dyslipidemia may be one of the potential risk
Relationships between dyslipidemia and progression or regression of diabetic nephropathy

The stages in diabetic renal disease were mentioned by Mogensen in 1983.[20] According to this theory, elevated urinary albumin excretion and following persistent proteinuria are the important manifestations of diabetic nephropathy, and many studies defined them as surrogate markers for end-stage renal disease.

Some cohort studies of diabetic patients have proven the risk factors associated with the progression or regression of the staging. Regarding the development of micro and macroalbuminuria, a cohort study of 27,805 type 1 diabetes with 2.5 years follow-up revealed that, besides diabetes duration and glycosylated hemoglobin, dyslipidemia is a risk factor for developing albuminuria.[21] A cohort study of 574 type 2 diabetes followed up for 7.8 years also revealed that, as well as high mean blood pressure and
hyperglycemia, high plasma cholesterol levels are main risk factors for development of dyslipidemia.[22] In this study, the participants with the combination of these three risk factors are a high-risk group for progression to diabetic nephropathy.

Associations between reduction of urinary albumin and dyslipidemia were reported in a cohort study of 386 patients with type 1 diabetes.[23] In this study, along with low levels of glycosylated hemoglobin and low systolic blood pressure, low levels of both cholesterol and triglycerides were independently associated with regression of microalbuminuria. Moreover, these factors had additive effects on regression of microalbuminuria.

A small number of studies reported the associations between dyslipidemia and loss of renal functions. Regarding the rate of decline in glomerular filtration rate (GFR), a prospective study of 30 patients with type 1 diabetes revealed that high serum cholesterol, triglycerides and apolipoprotein B were correlated to rapid decline in glomerular filtration
As described above, evidences have been accumulated to suggest that dyslipidemia is one of the risk factors for progression and regression of diabetic nephropathy. However, as far as we knew, there have been few studies reporting the association with end-stage renal disease, or renal replacement therapy. A report of a scientific workshop sponsored by the National Kidney Foundation (NKF) and the US Food and Drug Administration (FDA) indicated that evidences were insufficient to use a change of albuminuria as a surrogate marker as clinical endpoints.[25] Long-term follow-up studies are needed to demonstrate the causal relationships between dyslipidemia and end-stage renal disease from diabetic nephropathy.

**Treatment of dyslipidemia and diabetic nephropathy**

In regards to the treatment of dyslipidemia in patients with diabetes, there were some interventional trials of antihypercholesterolemic
agents including fibrates and statins.

The Diabetes Atherosclerosis Intervention Study (DAIS) is a randomized study that assessed the effect of fenofibrate on type 2 diabetic patients. [26] In this study, fenofibrate reduced the worsening of urine albumin excretion and the effects were mainly observed in the progression from normoalbuminuria to microalbuminuria. The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study is also a study evaluating the effect of fenofibrate on type 2 diabetes. [27] From this study, it was proved that fenofibrate is effective in lowering the decline of the estimated glomerular filtration rate (eGFR) and reducing the progression of albuminuria. Additionally in this study, patients treated with fenofibrate had higher rates of regression of albuminuria than the placebo group. This evidence suggests that fenofibrate is effective on ameliorating diabetic nephropathy. In meta-analysis of these two studies, significant effect on the regression from microalbuminuria to normoalbuminuria was proved, however, progression from microalbuminuria to macroalbuminuria was not
The effect of statins on diabetic nephropathy was examined in the Collaborative Atorvastatin Diabetes Study (CARD S). Treatment with atorvastatin was compared with a placebo in this study, and was associated with the improvement of annual changes in eGFR (0.18 mL/min/1.73m²/year). It is worthy to note that atorvastatin ameliorated eGFR without improving albuminuria, when comparing ACE inhibitors which have renoprotective effects and prevent the onset of albuminuria.[30]

There is still a lot of uncertainty about the effect of statins. The effect on renal protection was not demonstrated in the Study of Heart and Renal Protection (SHARP) which included 2094 (33%) participants with diabetes[31], and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) which included 3638 (36%) participants with diabetes. [32] Meta-analysis also showed that changes in eGFR[28] and regression of albuminuria[33] were not observed in patients with diabetes treated with statins.
There seems to be no definite answer for treatment of dyslipidemia in diabetic patients from the viewpoint of anti-hyperlipidemic agents. One of the supposed causes of inconsistency in results is that the kidney diseases in patients with diabetes may not be uniform, but consist of many renal diseases[34]. In some cases, renal biopsies might be needed to assess the accurate risks[35].

Diabetic patients are at higher risk for cardiovascular mortality compared with non-diabetic patients.[10][36] Statins have enough evidence, such as SHARP[31], of reducing the risk of cardiovascular events. Considering these facts, many diabetic patients might receive benefit from treatment of statin. Actually, more and more patients are receiving this treatment. In the analysis of the National Health and Nutrition Examination Survey (NHANES) 2005-2006, 93.5% of diabetic men aged 65-69 without cardiovascular disease received statin therapy.[37]

On the other hand, administration of statin may have adverse side effects, including myopathy[38], renal toxicity[39], and incident diabetes.[40]
A study comparing the risks and benefits of statins concluded that cardiovascular benefits outweigh the increased risk of new-onset diabetes.[41] It is beyond doubt that each patient’s risk must be taken in before administration of statins.

Another thing to keep in mind is that changes in lifestyle. The difficulty lies in improving renal and cardiovascular events through lifestyle changing.[42] It remains a challenge for future research to examine the impact of lifestyle changes.

Concluding remarks and future directions

In considering the complexity in the problem of diabetic nephropathy, many aspects of the patient’s conditions and treatments should be taken into account. Further insight into pathogenesis of dyslipidemia, and the risk and benefits of each treatment may be beneficial for each patient.

Acknowledgments
This study was supported in party by a Grant-in-Aid for Diabetic Nephropathy Research from the Ministry of Health, Labor and Welfare of Japan.

Conflict of interest: The authors have declared that no conflict of interest exists.


infarction in 52 countries (the INTERHEART study): a case-control study.


37. Robinson JG, Booth B. Statin use and lipid levels in older adults:

38. Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson T a,
Leitersdorf E, et al. Risk for myopathy with statin therapy in high-risk
patients. Archives of internal medicine. 2003;163:553–64.

39. Alsheikh-Ali A a, Ambrose MS, Kuvin JT, Karas RH. The safety of
rosuvastatin as used in common clinical practice: a postmarketing analysis.

40. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM.
Risk of incident diabetes among patients treated with statins: population

Statins, risk of diabetes, and implications on outcomes in the general